Raymond James Upgrades Vitalhub (TSE:VHI) to “Moderate Buy”

Vitalhub (TSE:VHI) was upgraded by investment analysts at Raymond James to a “moderate buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other research analysts have also issued reports on VHI. Scotiabank set a C$14.00 price target on Vitalhub and gave the stock an “outperform” rating in a research report on Thursday, January 30th. Canaccord Genuity Group increased their target price on Vitalhub from C$12.00 to C$12.50 and gave the company a “buy” rating in a research note on Thursday, January 16th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of C$11.92.

Vitalhub Price Performance

Shares of TSE VHI opened at C$9.66 on Wednesday. Vitalhub has a fifty-two week low of C$5.80 and a fifty-two week high of C$12.09. The firm has a market capitalization of C$522.53 million, a P/E ratio of 157.12, a P/E/G ratio of 1.18 and a beta of 1.26. The company’s 50 day simple moving average is C$10.49 and its 200 day simple moving average is C$10.31.

About Vitalhub

Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.